Corporate Satellite Symposia and Education Theater Schedule

Abstract:

It is up to us to make the first move. Talking about sexual health or fertility issues with a clinician is fairly uncomfortable for many; now imagine how hard it is for people with cancer. With all the perplexing and competing priorities to discuss, the chance of patients initiating topics of sex and intimacy are slim. This presentation is designed to make that conversation easier, it contains suggestions for you to help patients better understand how cancer could affect their fertility and sexuality and what they can do about it.

Learning Objectives:

1. Review the current landscape on sexual health and fertility in patients with cancer
2. Discuss the patient related and provider related barriers to providing care around sexual health and fertility issues
3. Identify strategies to provide education and support to patients concerned about or experiencing sexual health or fertility issues

Speaker(s): Kristen Mendez, MSN, APRN, CPNP-AC, CPHON, BMTCN, NE-BC, NPD-BC
Sponsored by: Servier Pharmaceuticals, LLC

Learning Objectives:

1. Review the latest Gene Therapy clinical data for the treatment of SCD and TDT; discuss clinical outcomes according to age of treatment with transformative therapies in SCD and TDT patients.

Faculty: Rabi Hanna, M.D.; Chairman of the Division of Pediatric Hematology & Oncology and BMT at Cleveland Clinic Children's

Synopsis of the Program: This symposium will review the latest available clinical data for Gene Therapy in patients with hemoglobinopathies, spanning FDA-approved treatment and ongoing therapies in development; in addition, available published data on the clinical outcomes according to age of treatment with transformative therapies (gene therapy and bone marrow transplant) will be discussed.

Supported by: Vertex Pharmaceuticals

Learning Objectives:

1. Discuss barriers to care, guidelines, and clinical evidence supporting the use of recombinant Erwinia-derived asparaginase for pediatric and AYA patients with ALL/LBL
2. Adapt team-based management plans to include alternative Erwinia-derived asparaginase for pediatric and AYA patients with ALL/LBL, as informed by the monitoring of hypersensitivity and other adverse developments
3. Employ collaborative care protocols to address practical aspects of Erwinia-derived asparaginase, including flexible dosing, therapeutic vigilance, and safety management

Faculty: Potential Chair and Faculty Member include, but are not limited to:

• Rachel A. Egler, MD; Case Western Reserve University School of Medicine
• Luke Maese, DO; University of Utah Health
• Michael J Burke, MD; Medical College of Wisconsin
• Elizabeth A. Raetz, MD; NYU Langone Health
• Rachel Rau, MD; University of Washington, Seattle Children's Hospital
• Lewis B. Silverman, MD; Dana-Farber Cancer Institute

Synopsis of the Program:

This Clinical Consults program uses expert-led cases and mini-lectures to review asparaginase’s central role in ALL/LBL therapy, challenges with toxicity and inactivation, recognition of hypersensitivity, evidence for recombinant Erwinia and new dosing strategies, sequential treatment planning for pediatric/AYA patients, and best practices for monitoring serum activity and ensuring safe, uninterrupted therapy.

Accredited Provider: PVI, PeerView Institute for Medical Education and Supported by Jazz Pharmaceuticals

Learning Objectives:

1. Review the challenges associated with managing patients with pLGG
2. Explore the role of MAPK pathway inhibition in the clinical management of pLGG
3. Review updated clinical efficacy and safety profile of a Type II RAF inhibitor
4. Discuss hypothetical patient cases with R/R pLGG

Faculty: 

• Caroline Hastings, MD; University of California, San Francisco

Supported by: Day One Biopharmaceuticals, Inc

Learning Objectives:

1. Identify barriers and facilitators to treatment adherence and independence among children and adolescents with hemophilia to guide personalized approaches to self-management and transition readiness
2. Evaluate current and emerging evidence on non-factor prophylaxis therapies, including rebalancing approaches that modulate natural anticoagulants, to inform individualized care decisions in hemophilia A and B
3. Apply evidence-based strategies for early detection, monitoring, and prevention of hemophilic arthropathy to preserve joint function and improve long-term quality of life.
4. Implement practical approaches to support patients and caregivers in overcoming barriers to injections and developing self-administration skills that foster adherence, confidence, and independence in hemophilia management.
5. Engage patients and caregivers in shared decision-making discussions that balance treatment goals, quality-of-life priorities, and preferences regarding prophylaxis administration and ongoing disease management.

Faculty:

• Guy Young, MD; Steven Pipe, MD; Amy Dunn, MD; Stacy Crouteau, MD MMS; Amy Shapiro, MD; Steven Lentz, MD

Synopsis of the Program:
This case-based symposium highlights real-world data and resources from a hemophilia clinic intervention, focusing on individualized prophylaxis, integration of non-factor therapies, self-management readiness, and joint health preservation to improve outcomes and quality of life for pediatric and adolescent patients.

Supported by: Sanofi US

Learning Objectives:

1. Describe the pathophysiology of VWD and mechanisms of von Willebrand factor relevant to the presentation in pediatric patients
2. Differentiate between recombinant and plasma-derived VWF products, incorporating PK/PD considerations into individualized treatment selection for pediatric patients
3. Integrate evidence-based strategies to individualize treatment plans for pediatric patients with VWD

Faculty: 

• Madvhi Rajpurkar, MD (Children’s Hospital of Michigan)
• Veronica Flood, MD (Children’s Wisconsin, Medical College of Wisconsin)

Synopsis of the Program:

Children with von Willebrand disease (VWD) often experience delayed diagnosis, non-individualized treatment, and poor management of comorbid bleeding symptoms, such as heavy menstrual bleeding, recurrent epistaxis (nosebleeds), and anemia. This session aims to improve the pediatric hematology team’s knowledge, confidence, and skills related to caring for patients with confirmed or suspected pediatric VWD.

Accredited provider: 

This activity is jointly provided by The France Foundation and the International Society on Thrombosis and Haemostasis (ISTH). In support of improving patient care, this activity has been planned and implemented by The France Foundation and ISTH. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

• Physician credit designation: The France Foundation designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• All other health care professionals completing this course will be issued a statement of participation.

Supported by: Takeda

Faculty: Dr. Guy Young, MD; Children's Hospital Los Angeles; Director, Hemostasis and Thrombosis Program; Professor of Pediatrics, Keck School of Medicine of USC

Synopsis of the Program: We will review the basic science of plasminogen deficiency type 1 (PLGD 1), its autosomal recessive inheritance, how ligneous lesions can appear on mucous membranes, and how to diagnose PLGD 1. We will also introduce the FDA approved treatment, discuss clinical trial results, and show patient case studies.

Supported by: Kedrion Biopharma